KPTI News and Press, Karyopharm Therapeutics Inc. From 06/22/20

-- XPOVIO is Now the Only Single-Agent, Oral Therapy Approved for the Treatment of Patients with Relapsed or Refractory Diffuse Large B-cell Lymphoma, Including DLBCL Arising from Follicular Lymphoma -- -- XPOVIO is the First and Only FDA-Approved Drug for Use in Both M...

Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. A podcast of Stocks to Watch is also available on Sundays on Seeking Alpha , Apple ...

Karyopharm Doses First Patient in Brain Cancer Trial Karyopharm Therapeutics ( KPTI ) announced that it has dosed the first patient for its Phase 1/2 clinical trial. The study aims to assess the potential of oral Selinexor in combination with standard of care therapy in treating patients...

NEWTON, Mass., June 12, 2020 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), an innovation-driven  pharmaceutical company, today announced that eight posters relating to XPOVIO® (selinexor), the Company’s first-in-class, oral Selective Inhibitor of Nuclear E...

Market Pulse The question of whether it's a new bull market rally or just an intermittent bear market rally doomed to end later this year will most likely be decided late in the third quarter or during the fourth quarter when enough evidence on the durability of the recovery pace is forthcom...

The first patient has been dosed in an open-label 402-subject  Phase 1/2 clinical tria l evaluating Karyopharm Therapeutics' ( KPTI -2.0% ) lead drug selinexor, compared to standard-of-care treatment, in patients with newly diagnosed or recurrent glioblastoma, an aggressive type of ...

NEWTON, Mass., June 09, 2020 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), an innovation-driven pharmaceutical company, today announced dosing of the first patient in a Phase 1/2 clinical study evaluating oral selinexor in combination with standard of care therapy in patie...

Karyopharm Therapeutics (NASDAQ: KPTI ) announces detailed results from a Phase 3 clinical trial, BOSTON , evaluating Xpovio (selinexor), combined with Takeda's Velcade (bortezomib) and low-dose dexamethasone, in multiple myeloma patients who had received one-to-three prior lines of thera...

-- Combination of Once-Weekly XPOVIO ® (selinexor), Once-Weekly Velcade ® (bortezomib) and Dexamethasone (SVd) Prolonged Median Progression-Free Survival by 47% Compared to Standard Twice-Weekly Velcade ® plus Dexamethasone (Vd) -- -- SVd Was Superior to Vd Acros...

It should first be noted we did not consult with Epizyme, Inc. in the preparation of this article. Our analysis concludes Epizyme, Inc.'s (EPZM) is an incredible company and EPZM's product Tazverik could have a bright future treating those who suffer from Follicular Lymphoma. EPZM's Tazverik...